GlassScriptPhysician profile
Christine E Armstrong
NPI 1669787354
$2,842.45
in general payments reported to CMS, 2019-2025
19 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2023: $676 · 2024: $711 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $368.77 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $260.57 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $243.58 | 2024-2025 | Auvelity, Symbravo |
| Abbvie INC. | $243.56 | 2021-2023 | |
| Edwards Lifesciences Corporation | $149.45 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Madrigal Pharmaceuticals | $148.28 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $133.83 | 2024 | |
| Alnylam Pharmaceuticals INC. | $124.99 | 2025 | Amvuttra |
| Argenx US, INC. | $122.88 | 2025 | Vyvgart |
| Jazz Pharmaceuticals INC. | $122.76 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.10 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $120.34 | 2025 | Arexvy |
| Sage Therapeutics, LLC | $110.87 | 2024 | |
| Ferring Pharmaceuticals INC. | $105.07 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $99.63 | 2023 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $98.67 | 2025 | Cologuard Collection Kit |
| United Therapeutics Corporation | $94.88 | 2025 | |
| Sanofi-Aventis U.S. LLC | $90.22 | 2024 | |
| Gilead Sciences, INC. | $83.00 | 2023 | Descovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.